Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1953 1
1954 8
1955 6
1956 7
1957 4
1958 3
1959 3
1960 3
1961 3
1962 5
1963 5
1964 11
1965 6
1966 7
1967 6
1968 8
1969 10
1970 13
1971 6
1972 13
1973 8
1974 8
1975 6
1976 7
1977 8
1978 10
1979 2
1980 7
1981 3
1982 5
1983 11
1984 8
1985 5
1986 4
1987 6
1988 9
1989 5
1990 10
1991 12
1992 16
1993 13
1994 12
1995 10
1996 12
1997 7
1998 9
1999 3
2000 3
2001 8
2002 3
2003 7
2005 5
2006 2
2007 4
2008 2
2009 1
2010 4
2011 2
2012 3
2015 6
2016 4
2017 5
2018 6
2019 11
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

421 results
Results by year
Filters applied: . Clear all
Page 1
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
Kappos L, et al. N Engl J Med 2010 - Clinical Trial. Among authors: Burtin P. PMID 20089952 Free article.
The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 for either dose vs. placebo). Fingolimod at doses of 0.5 mg and 1.25 mg significantly reduced the risk of disability progression over the 24-month period (hazard ratio, 0.70 and 0.68, respectively; P=0.02 vs. placebo, for both comparisons). ...
The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 fo …
Mortality after surgery in Europe: a 7 day cohort study
Pearse RM, et al. Lancet 2012 - Clinical Trial. PMID 22998715 Free PMC article.
Significance was set at p<0·05. We constructed multilevel logistic regression models to adjust for the differences in mortality rates between countries. ...After adjustment for confounding variables, important differences remained between countries when compared with the UK, the country with the largest dataset (OR range from 0·44 [95% CI 0·19-1·05; p=0·06] for Finland to 6·92 [2·37-20·27; p=0·0004] for Poland). ...
Significance was set at p<0·05. We constructed multilevel logistic regression models to adjust for the differences in mortality ra …
Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database
Cortegiani A, et al. Crit Care 2018 - Clinical Trial. PMID 29895331 Free PMC article.
Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%; p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life-sustaining measures were significantly more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). ...
Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%; p < 0.0001), despite similar …
421 results
Jump to page
Feedback